CO2019003858A2 - Formulaciones de cisteamina y derivados de cisteamina - Google Patents

Formulaciones de cisteamina y derivados de cisteamina

Info

Publication number
CO2019003858A2
CO2019003858A2 CONC2019/0003858A CO2019003858A CO2019003858A2 CO 2019003858 A2 CO2019003858 A2 CO 2019003858A2 CO 2019003858 A CO2019003858 A CO 2019003858A CO 2019003858 A2 CO2019003858 A2 CO 2019003858A2
Authority
CO
Colombia
Prior art keywords
cysteamine
formulations
derivatives
dry
neurodegenerative disorders
Prior art date
Application number
CONC2019/0003858A
Other languages
English (en)
Spanish (es)
Inventor
Marco Barchielli
Paolo Colombo
Alessandra Rossi
Greta Adorni
Original Assignee
Recordati Ind Chimica E Farmaceutica Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Ind Chimica E Farmaceutica Spa filed Critical Recordati Ind Chimica E Farmaceutica Spa
Publication of CO2019003858A2 publication Critical patent/CO2019003858A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CONC2019/0003858A 2016-10-11 2019-04-16 Formulaciones de cisteamina y derivados de cisteamina CO2019003858A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16193180.3A EP3308773A1 (fr) 2016-10-11 2016-10-11 Formulations de cystéamine et de dérivés de cystéamine
PCT/EP2017/075801 WO2018069313A1 (fr) 2016-10-11 2017-10-10 Formulations de cystéamine et de dérivés de cystéamine

Publications (1)

Publication Number Publication Date
CO2019003858A2 true CO2019003858A2 (es) 2019-04-30

Family

ID=57130210

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0003858A CO2019003858A2 (es) 2016-10-11 2019-04-16 Formulaciones de cisteamina y derivados de cisteamina

Country Status (13)

Country Link
US (1) US10813888B2 (fr)
EP (2) EP3308773A1 (fr)
JP (1) JP2019533668A (fr)
KR (1) KR102321156B1 (fr)
AU (1) AU2017341350B2 (fr)
BR (1) BR112019006049A2 (fr)
CA (1) CA3034554A1 (fr)
CO (1) CO2019003858A2 (fr)
EA (1) EA201990540A1 (fr)
IL (1) IL264898B2 (fr)
MX (1) MX2019003300A (fr)
UA (1) UA123838C2 (fr)
WO (1) WO2018069313A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
US7863288B2 (en) 2005-06-22 2011-01-04 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
AU2007210005C1 (en) 2006-01-27 2014-01-23 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
EP2172203A1 (fr) 2008-09-17 2010-04-07 Giuliani S.P.A. Compositions pharmaceutiques pour le traitement de troubles d'irritation gastrointestinale
EP2483761A4 (fr) * 2009-09-08 2014-08-27 Qualcomm Inc Écran tactile avec une amélioration de vitesse z
EP2968569A4 (fr) * 2013-03-15 2016-11-02 Argenta Mfg Ltd Formulation à mâcher
TWI649100B (zh) * 2013-06-17 2019-02-01 地平線罕見醫學製藥有限責任公司 延遲釋放型半胱胺珠粒調配物，以及其製備及使用方法
CN103652366B (zh) 2013-09-17 2017-07-07 杭州康德权饲料有限公司 一种稳定微囊包膜半胱胺盐酸盐及其制备方法
WO2016005994A2 (fr) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Composition pharmaceutique comprenant une dispersion solide de médicaments de classe ii bcs avec gelucires

Also Published As

Publication number Publication date
AU2017341350A1 (en) 2019-03-07
AU2017341350B2 (en) 2023-03-23
JP2019533668A (ja) 2019-11-21
IL264898A (en) 2019-05-30
EP3525761A1 (fr) 2019-08-21
KR102321156B1 (ko) 2021-11-03
BR112019006049A2 (pt) 2019-06-25
CA3034554A1 (fr) 2018-04-19
MX2019003300A (es) 2019-05-22
EP3308773A1 (fr) 2018-04-18
WO2018069313A1 (fr) 2018-04-19
KR20190057341A (ko) 2019-05-28
IL264898B1 (en) 2023-03-01
UA123838C2 (uk) 2021-06-09
IL264898B2 (en) 2023-07-01
US10813888B2 (en) 2020-10-27
EA201990540A1 (ru) 2019-08-30
US20190216741A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
CL2018003142A1 (es) Moduladores de la vía de estrés integrada
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017000902A1 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2017001124A1 (es) Agentes inmunomoduladores
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
ECSP19015192A (es) Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos
CU20190101A7 (es) Imidazopirimidinas diazabicíclicas sustituidas
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
CL2015002546A1 (es) Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
CL2016001587A1 (es) Derivado basado en 1,2-naftoquinona y método de preparación del mismo.
CL2017001073A1 (es) 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos
CL2017000715A1 (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2019001053A1 (es) Formulaciones farmacéuticas y métodos para prepararlas.
MA46641A (fr) Méthodes et compositions permettant d&#39;empêcher la transmission de maladies propagées par un vecteur
CL2021000930A1 (es) Piridazinas novedosas
CL2017000244A1 (es) Formulaciones de compuestos biológicos para instilación intravesical.
CL2015003433A1 (es) Derivados de tilosina y método para su preparación
AR108616A1 (es) Formulación combinada de tres compuestos antivirales